Background -Leukotriene (LT) B4 is a potent neutrophil chemoattractant and also stimulates eosinophils in vitro, but its role in asthmatic inflammation is unknown. Methods -The effect of the novel LTB4 receptor antagonist, LY293111, was examined using allergen challenge as a model for asthmatic inflammation in 12 atopic asthmatic subjects in a double blind placebo controlled crossover trial. Subjects with an established early (EAR) and late asthmatic response (LAR) to allergen at screening received oral LY293111 in a dose of 112 mg three times daily for seven days or placebo before further allergen challenge. Each treatment was separated by a washout period of 28 days. Individuals underwent histamine challenge one hour before and three hours after allergen challenge. Bronchoalveolar lavage (BAL) fluid was obtained at bronchoscopy 24 hours after allergen challenge. Results -There was no difference in baseline lung function, EAR, LAR, or in airway responsiveness to histamine before and after allergen between placebo and LY293111. By contrast, treatment with LY293111 significantly reduced the number of neutrophils in BAL fluid expressed as both absolute cell numbers and percentage cell differential counts: absolute cell counts, median (range) 0.04 (0.02-0.15) x 106 after LY293111, 0.09 (0.02-0.43) x 106 after placebo; percentage differential cell counts 0.35 (0.1-2.0) after LY293111, 0.80 (0.1-3.6) after placebo (p<0.05). Eosinophils, macrophages, and lymphocytes in BAL fluid did not differ between treatments. There was a significant reduction in the concentration of myeloperoxidase (MPO) with both placebo (16 (6.6) ng/ml) and LY293111 (3.5 (1.8) ng/ml) and of LTB4 (placebo 4.6 (1.2) pg/ml, LY293111 2.2 (0.2) pg/ml). Concentrations of LTC4 and interleukin 8 were reduced, although not significantly, whereas concentrations ofinterleukin 6, GM-CSF, and TNF-a were unchanged by LY293111.
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Conclusions -These results demonstrate an influence of LTB4 on neutrophil influx and activation in the airway following allergen challenge. Despite this anti-inflammatory effect, there was no measured physiological benefit and this questions the functional role of the neutrophil in the pathophysiology of allergen induced asthma.
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Airway inflammation in asthma is associated with the release of multiple inflammatory mediators including several lipid derived mediators.' The leukotrienes (LTs) are a family of molecules that evolve from arachidonic acid metabolism via the 5-lipoxygenase pathway. The cysteinyl leukotrienes C4, D4, and E4 are potent bronchoconstrictors, affect airway responsiveness, increase vascular permeability, and increase mucus production.2 By contrast, LTB4 is a potent chemoattractant and activator of neutrophils without significant effect on airway smooth muscle.3 Inhaled LTB4 has no significant effect on airway function when given by inhalation to patients with asthma,4 although it does increase the number of neutrophils in bronchoalveolar lavage (BAL) fluid. 5 The late asthmatic response (LAR) to inhaled allergen is associated with airway inflammation and increased airway hyperresponsiveness.6 The cellular response is characterised by increased migration of eosinophils to the airway.7 Allergen induced airway changes are likely to be influenced by complex inflammatory events involving cell-cell interactions through cytokine networks as levels of interleukins IL-1, IL-2, IL-5, IL-6, IL-8, tumour necrosis factor ot (TNF-ct), and granulocyte-macrophage colony stimulating factor (GM-CSF) are increased in BAL fluid from asthmatic subjects 18 
Methods

PROTOCOL
The study protocol was approved by the ethics committee of the Royal Brompton Hospital NHS Trust and informed written consent was obtained from all subjects. A randomised A washout period of 28 days elapsed before subjects crossed over to the second treatment period. On completion ofboth treatments, subjects reattended for a final visit one week later to confirm that asthma symptoms were stable. Routine biochemistry and haematology were checked at screening, before and after both treatment periods, and at follow up.
The compliance of each individual was assessed by assay of plasma levels of LY293111 before and after each treatment period.
ALLERGEN AND PC20 CHALLENGE
All challenge tests were performed using a nebuliser attached to a breath activated dosimeter (MB3, MEFAR, Bovezzo, Italy). The nebuliser delivered particles with an aerodynamic mass median diameter of 3.5-4 gm at an output of 9 jtl per breath. The nebuliser was set to nebulise for one second with a pause time of six seconds at a pressure of 22 pounds per square inch.
Airway responsiveness was measured by each subject inhaling doubling concentrations ofhistamine from 0.03 mg/ml to 32 mg/ml until the FEV, fell by 20%. The provocative concentration (PC20) was derived by linear interpolation of log dose-response curves.
Freeze dried allergen extracts (Aquagen SQ, Allerayde, Nottingham, UK) were used for allergen challenge. At screening known dilutions of the allergen were made to give final concentrations of 200, 1000, 2500, 5000, 12500, 25000, and 50000 IU/ml. The initial dose of allergen was 200 IU/ml, and FEV, was measured five and 10 minutes after allergen dose. Serially increasing doses of allergen were inhaled and the cumulative dose resulting in a 15% reduction in FEVy within 10 minutes was recorded as constituting an adequate allergen challenge for the early asthmatic response (EAR). The FEV, was measured every 15 minutes for the first hour and hourly thereafter.
The LAR was defined as a fall in FEVy of greater than 15% between four and 10 hours. For subsequent allergen challenges the cumulative dose used at screening was given as a single concentration at the end of each treatment period.
All bronchodilators were withheld for eight hours before the inhalation challenge. At 21-24 hours following allergen challenge, 30 minutes before bronchoscopy, subjects were treated with nebulised salbutamol 2.5 mg and, after bronchoscopy, were rescued with nebulised budesonide 2 mg and, if required, with further bronchodilator. All subjects monitored peak flows for 24 hours at home following discharge.
BRONCHOSCOPY AND BRONCHOALVEOLAR LAVAGE (BAL)
All subjects underwent bronchoscopic examination 21-24 hours after allergen challenge following an overnight fast. The fibreoptic bronchoscope (Olympus, Keymed Ltd, Southend, UK) was introduced via the nose following local anaesthesia induced by lignocaine 4%, after sedation with midazolam 5 mg intravenously. The bronchoscope was wedged in the right middle lobe. After instillation of 240 ml of warmed sterile 0.9% saline BAL fluid was retrieved and the total volume was recorded.
Pooled BAL fluid was stored on ice, centrifuged at 300 g, and the supernatant collected and frozen at -70'C after recording the volume. A total cell count and cell viability count, using trypan blue exclusion, were taken and the pellet was resuspended at a concentration of 1 o6 cells/ml. Cytospins were made using 100 pl of cell suspension.
CELL DIFFERENTIAL COUNTS
From the cytospins Giemsa stained slides were prepared for differential cell counts and were examined under light microscopy. The percentages of eosinophils, neutrophils, alveolar macrophages, lymphocytes, and epithelial cells were recorded. A minimum of 1500 cells was counted.
ANALYSIS OF BAL FLUID
Concentrations of prostaglandins, leukotrienes, myeloperoxidase, and cytokines were measured using an enzyme linked immunosorbent assay (ELISA). Individual samples were assayed using specific ELISA kits for leukotriene B4 (LTB4), leukotriene C4 (LTC4), prostaglandin D, (PGD2), prostaglandin F2, (PGF2J), prostacyclin (PGI2), thromboxane B2 (TXB2), and myeloperoxidase (MPO) (all Caymen Chemical Company, Ann Arbor, Michigan, USA) and for interleukin (IL)-6, IL-8, tumour necrosis factor ct (TNFoL), and granulocyte-macrophage colony stimulating factor (GM-CSF) (all R&D Systems, Minneapolis, Minnesota, USA). Study samples and standards for each were assayed separately and in duplicate in accordance with the kit manufacturer's instructions. The optical density for each was read on the microplate autoreader set at 450 nm (Molecular Devices, UV-MAX, Menlo Park, California, USA). The mean net optical density of the standards was plotted and the individual sample concentrations were read from the standard curves. For each assay all samples were analysed on the same day in a blinded fashion. Results are expressed as the mean of the duplicate samples. According to the manufacturers, none of the assay kits showed any cross reactivity with any other cytokine, leukotriene, or prostaglandin.
DATA ANALYSIS
Airway data are expressed as means (SE) and, for airway responsiveness, PC20 data are expressed as the geometric means (SE). The extent of the LAR was assessed by the maximal fall in the FEV, and expressed as the percentage change from the baseline value after diluent. All PC20 histamine values were log transformed for analysis.
The effect of allergen on airway responsiveness to histamine was calculated using the formula: log2PC20 hist (pre-allergen) -log2PC20 hist ( were reduced but not significantly. Finally, LY293111 did not alter either the LAR or allergen induced increase in airway responsiveness. The LAR after inhaled allergen is characterised by increased migration of eosinophils to the airway7 and there is some evidence to support an increase in the number of neutrophils. 9 We have shown that LY293111 caused a significant reduction in neutrophils, MPO (a marker of neutrophil activation), and LTB4 (a potent neutrophil chemoattractant which is synthesised in large numbers by neutrophils '5) without any effect on the LAR. This suggests that neutrophils are not important in the development of allergen induced airway obstruction. It is possible that the failure to demonstrate a clinical effect is due to lack of efficacy of the active drug. This is unlikely as other studies with this compound have confirmed that it is a potent and specific receptor antagonist producing complete blockade of LTB4 in vitro"3 and abolition of the inflammatory response to intradermal LTB4 in vivo.14 The latter study was the first clinical report of this compound to confirm that LY293 111 is a potent LTB4 receptor antagonist in humans, thus validating its use in our study. We chose the same dose three times daily, the highest dose for which safety and pharmacokinetic data are available from phase I volunteer clinical trials (Lilly Research Laboratories, data on file). As the compound has an elimination half life of 7-12 hours, steady state levels were likely to have been achieved within 72 hours. Furthermore, all the subjects were compliant demonstrating satisfactory plasma levels on the day of allergen following treatment with LY293 111.
The lack of clinical effect may be due to the patient population examined. All the subjects had an FEV, in excess of 80% and a geometric mean PC20 of 0.5 mg/ml. The group were mild asthmatics who did not require inhaled steroids and therefore failure to demonstrate a clinical effect of LY293 111 using allergen challenge as a model of asthma in this population may not be predictive for patients with more severe asthma. Furthermore, the levels of neutrophils, eosinophils, and inflammatory cytokines in the BAL fluid were lower than in other studies of patients with impaired lung function exhibiting either spontaneous or allergen induced symptoms. ' The BAL fluid populations of alveolar macrophages and lymphocytes after allergen challenge were unaffected by treatment. Compatible with this finding, there was no change in concentrations of GM-CSF and IL-6, cytokines predominantly released from monocytes and alveolar macrophages and, to a lesser extent, from lymphocytes.25 Also, levels of TNFoa, which is released in abundance from alveolar macrophages, did not differ between treatments. However, there was a tendency to reduced levels of IL-8 after LY293 111. Although this effect was not statistically significant, it requires explanation. IL-8 is a pro-inflammatory cytokine that is a potent chemoattractant for and activator of neutrophils with lesser effects on eosinophils. It is synthesised and released by several inflammatory cells within the airway including macrophages, activated lymphocytes, epithelial cells, and neutrophils.25 Increased levels of IL-8 have been found in the BAL fluid of asthmatic subjects 18 hours after allergen, although its cellular source was unclear.8 As LY293111 did not change the numbers of macrophages or lymphocytes in the BAL fluid, it is unlikely that an effect on the release of IL-8 from these cells could account for its partial decrease. Although speculative, it is possible that neutrophils are an important source of IL-8 after allergen and that a reduction in the neutrophil count by LY293 111 led to a decrease in IL-8 levels in BAL fluid. Alternatively, IL-8 may have been generated by epithelial cells which, in our study, were almost undetectable in the BAL fluid. Irrespective of the source of the IL-8, we did not see changes in eosinophil numbers even though the IL-8 level fell with treatment. This suggests either that IL-8 is not critical for recruitment of eosinophils following allergen challenge or that the small changes demonstrated for this cytokine are insufficient to exhibit an effect on eosinophil trafficking within the airway.
The concentrations of prostanoids in BAL fluid were unchanged between treatment periods. This is consistent with the lack of clinical effect. PGD2, PGF2,, and TXA2 (TXB2 is the stable metabolite) increase airway responsiveness, are potent bronchoconstrictors, and are likely to contribute to the LAR, whereas PGE2 and PGI2 relax airway smooth muscle and may inhibit the LAR.2627 PGD2 is released by several inflammatory cells after allergen challenge.26 The failure to observe differences in prostanoids is not surprising as LY2931 11 affected neutrophils and neutrophil-derived mediators only without influencing other cells or mediators of the LAR.
We have suggested that LTB4 influences allergen induced neutrophil activity in asthmatic airways. Without baseline data on BAL cell populations and mediator release we cannot be certain that our results represent allergen induced responses as the levels of eosinophils, neutrophils, and cytokines are lower than in other studies.'617 It is therefore possible that the effect of LTB4 receptor antagonism on neutrophils and airway inflammation would be observed even in unprovoked mild asthma. Nonetheless, we feel that our study relates to airway events stimulated by allergen as all the cytokines we measured are increased in the BAL fluid at 18 hours after allergen9 and several studies have confirmed that BAL fluid levels of eosinophils and neutrophils are increased after allergen.679 17 Regardless of this, challenge with sensitising agents other than allergen may be a more appropriate model to evaluate the clinical potential of LY293 111 and other drugs of this class in asthma. In view of our results, it is likely that these agents would reduce the late asthmatic responses to challenge with ozone and toluene diisocyanate which are characterised predominantly by an airway neutrophilia.2529 Furthermore, LY293111 may have therapeutic potential in other respiratory diseases where LTB4 and neutrophils are major inflammatory mediators such as chronic bronchitis, bronchiectasis, and cryptogenic fibrosing alveolitis. The role of LTB4 and the neutrophil in asthma therefore remains uncertain but could be clarified by further evaluation of potent inhibitors of LTB4 in challenge studies using sensitising agents or in clinical trials of patients with more severe disease.
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